GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » The Oncology Institute Inc (NAS:TOI) » Definitions » Revenue per Share

The Oncology Institute (The Oncology Institute) Revenue per Share : $4.63 (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is The Oncology Institute Revenue per Share?

The Oncology Institute's revenue per share for the three months ended in Mar. 2024 was $1.28. The Oncology Institute's revenue per share for the trailing twelve months (TTM) ended in Mar. 2024 was $4.63.

During the past 12 months, the average Revenue Per Share Growth Rate of The Oncology Institute was 34.00% per year. During the past 3 years, the average Revenue Per Share Growth Rate was 14.80% per year. During the past 5 years, the average Revenue Per Share Growth Rate was 16.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for The Oncology Institute's Revenue per Share or its related term are showing as below:

TOI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 9.1   Med: 14.8   Max: 20.4
Current: 14.8

During the past 6 years, The Oncology Institute's highest 3-Year average Revenue Per Share Growth Rate was 20.40% per year. The lowest was 9.10% per year. And the median was 14.80% per year.

TOI's 3-Year Revenue Growth Rate is ranked better than
62.52% of 587 companies
in the Healthcare Providers & Services industry
Industry Median: 9.7 vs TOI: 14.80

The Oncology Institute Revenue per Share Historical Data

The historical data trend for The Oncology Institute's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Oncology Institute Revenue per Share Chart

The Oncology Institute Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue per Share
Get a 7-Day Free Trial 2.41 2.91 3.07 3.13 4.40

The Oncology Institute Quarterly Data
Sep18 Dec18 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.04 1.08 1.12 1.16 1.28

Competitive Comparison of The Oncology Institute's Revenue per Share

For the Medical Care Facilities subindustry, The Oncology Institute's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


The Oncology Institute's PS Ratio Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, The Oncology Institute's PS Ratio distribution charts can be found below:

* The bar in red indicates where The Oncology Institute's PS Ratio falls into.



The Oncology Institute Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

The Oncology Institute's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Revenue Per Share (A: Dec. 2023 )=Revenue (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=324.239/73.749
=4.40

The Oncology Institute's Revenue Per Share for the quarter that ended in Mar. 2024 is calculated as

Revenue Per Share (Q: Mar. 2024 )=Revenue (Q: Mar. 2024 )/Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
=94.666/74.234
=1.28

Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


The Oncology Institute  (NAS:TOI) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


The Oncology Institute Revenue per Share Related Terms

Thank you for viewing the detailed overview of The Oncology Institute's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


The Oncology Institute (The Oncology Institute) Business Description

Traded in Other Exchanges
N/A
Address
18000 Studebaker Road, Suite 800, Cerritos, CA, USA, 90703
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services.
Executives
Havencrest Healthcare Partners, L.p. 10 percent owner 5221 N. O'CONNOR BLVD., SUITE 1200, IRVING TX 75039
Mihir Shah officer: Chief Financial Officer, other: Principal Financial Officer C/O 1668 S. GARFIELD AVENUE, 2ND FLOOR, ALHAMBRA CA 91801
Brad Hively director, officer: Chief Executive Officer C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Jeremy Castle officer: Chief Operating Officer 1800 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Richard A Barasch director, officer: Executive Chairman C/O UNIVERSAL AMERICAN FINANCIAL CORP, SIX INTERNATIONAL DRIVE SUITE 190, RYE BROOK NY 10573
Matthew P Miller officer: Chief Operating Officer C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Daniel Virnich officer: Chief Operating Officer C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Yale Podnos officer: Chief Medical Officer C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Diona Simoneit officer: Chief Accounting Officer, other: Principal Accounting Officer C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Mohit Kaushal director 44 SOUTH BROADWAY, WHITE PLAINS NY 10601
Gabriel Ling director C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Mark L Pacala director C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Richy Agajanian 10 percent owner C/O THE ONCOLOGY INSTITUTE OF HOPE, 18000 STUDEBAKER ROAD, SUITE 800, CERRITOS CA 90703
Maeve O'meara director C/O CASTLIGHT HEALTH, INC., 150 SPEAR ST., SUITE 400, SAN FRANCISCO CA 94105
Toi Hc I, Llc 10 percent owner 2100 MCKINNEY AVENUE, SUITE 1760, DALLAS TX 75201